Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using CSF1R-targeting Agent

Review the clinical trials studying csf1r-targeting agent on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 34 locations
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Status: Active
Location: 34 locations
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Status: Active
Location: 20 locations
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Status: Active
Location: 16 locations
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Status: Active
Location: 14 locations
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Status: Active
Location: 9 locations
Axatilimab and Olaparib for the Treatment of Patients with BRCA 1/2 and PALB2-Associated Metastatic HER2 Negative Breast Cancer
Status: Active
Location: 3 locations
Axatilimab in Combination with Nivolumab for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Location: 2 locations
AMB-05X for Treating Patients with ctDNA(+) Stage I-IV Colorectal Cancer after Curative-Intent Treatment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Axatilimab and Extracorporeal Photopheresis for the Treatment of Patients with Chronic Graft-versus-Host Disease
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Axatilimab for the Treatment of Sclerotic Chronic Graft-versus-Host Disease
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Nivolumab in Combination with BMS-986253 or Cabiralizumab Before Surgery for the Treatment of Newly Diagnosed Surgically Resectable, Recurrent or Metastatic Head and Neck Cancer, SPARK2 Study
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Axatilimab in Combination with Retifanlimab and Paclitaxel for the Treatment of Patients with Advanced or Metastatic Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Quizartinib, Decitabine, and Venetoclax in Treating Patients with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients with Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Ziftomenib and Quizartinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas